Marion Harris

9.2k total citations
36 papers, 795 citations indexed

About

Marion Harris is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marion Harris has authored 36 papers receiving a total of 795 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 19 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marion Harris's work include Pancreatic and Hepatic Oncology Research (23 papers), Cancer Genomics and Diagnostics (18 papers) and Neuroendocrine Tumor Research Advances (6 papers). Marion Harris is often cited by papers focused on Pancreatic and Hepatic Oncology Research (23 papers), Cancer Genomics and Diagnostics (18 papers) and Neuroendocrine Tumor Research Advances (6 papers). Marion Harris collaborates with scholars based in Australia, United States and Spain. Marion Harris's co-authors include Ingrid Winship, Merle Spriggs, David Goldstein, Michele Reni, E. Gabriela Chiorean, Wen Wee, Josep Tabernero, Daniel D. Von Hoff, Lawrence Cher and Salvatore U. Berlangieri and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

Marion Harris

32 papers receiving 766 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marion Harris Australia 14 504 199 198 179 117 36 795
Mariana Brandão Belgium 16 468 0.9× 200 1.0× 181 0.9× 154 0.9× 102 0.9× 65 721
Shelly Seward United States 15 390 0.8× 116 0.6× 157 0.8× 298 1.7× 144 1.2× 34 898
Jana Barinoff Germany 18 593 1.2× 269 1.4× 333 1.7× 159 0.9× 164 1.4× 49 976
Shuncong Wang China 16 349 0.7× 211 1.1× 98 0.5× 209 1.2× 69 0.6× 40 773
Ciara C. O’Sullivan United States 18 590 1.2× 262 1.3× 299 1.5× 293 1.6× 137 1.2× 72 1.0k
Claudia Andreetta Italy 16 517 1.0× 205 1.0× 296 1.5× 162 0.9× 81 0.7× 41 831
Hamdy A. Azim Egypt 19 766 1.5× 352 1.8× 252 1.3× 230 1.3× 141 1.2× 66 1.1k
Sara López‐Tarruella Spain 19 672 1.3× 240 1.2× 277 1.4× 228 1.3× 90 0.8× 89 962
Claudia Omarini Italy 14 507 1.0× 243 1.2× 267 1.3× 184 1.0× 97 0.8× 54 777
Aránzazu Manzano Spain 16 571 1.1× 308 1.5× 200 1.0× 240 1.3× 106 0.9× 58 1.1k

Countries citing papers authored by Marion Harris

Since Specialization
Citations

This map shows the geographic impact of Marion Harris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marion Harris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marion Harris more than expected).

Fields of papers citing papers by Marion Harris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marion Harris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marion Harris. The network helps show where Marion Harris may publish in the future.

Co-authorship network of co-authors of Marion Harris

This figure shows the co-authorship network connecting the top 25 collaborators of Marion Harris. A scholar is included among the top collaborators of Marion Harris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marion Harris. Marion Harris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burns, Christopher J., Terrie‐Anne Cock, Anthony C. Bishop, et al.. (2024). Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis.. Journal of Clinical Oncology. 42(16_suppl). e16337–e16337. 1 indexed citations
2.
Cao, Kim, Daphne Day, Katie N. Evans, et al.. (2024). Evaluating the impact of a tertiary multidisciplinary meeting in metastatic breast cancer: A prospective study. The Breast. 79. 103861–103861.
3.
Lee, Belinda, Daniel Croagh, Marion Harris, et al.. (2024). Mutated KRASas a promising target in pancreas cancer: PURPLE registry data to inform real-world incidence and prognostic significance and to aid trial recruitment.. Journal of Clinical Oncology. 42(16_suppl). 11150–11150. 1 indexed citations
4.
Tie, Jeanne, Yuxuan Wang, Serigne Lo, et al.. (2024). Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.. Journal of Clinical Oncology. 42(16_suppl). 108–108. 11 indexed citations
5.
Ross, Paul J., Harpreet Wasan, Daniel Croagh, et al.. (2021). Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open. 7(1). 100356–100356. 13 indexed citations
6.
Lundy, Joanne, Marion Harris, John Zalcberg, et al.. (2021). EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. Frontiers in Oncology. 11. 770022–770022. 5 indexed citations
7.
Barbour, Andrew P., Jaswinder S. Samra, Koroush S. Haghighi, et al.. (2020). The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. Annals of Surgical Oncology. 27(7). 2506–2515. 18 indexed citations
8.
9.
David, Steven, Gwo‐Yaw Ho, Daphne Day, et al.. (2020). Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature. Translational Oncology. 14(1). 100939–100939. 26 indexed citations
10.
Wong, Hui‐Li, Lara Lipton, Jeremy Shapiro, et al.. (2018). Use of folfirinox chemotherapy in an Australasian population of pancreatic cancer. Annals of Oncology. 29. ix60–ix61. 1 indexed citations
11.
12.
Chiorean, E. Gabriela, Daniel D. Von Hoff, Josep Tabernero, et al.. (2016). Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. British Journal of Cancer. 115(2). 188–194. 63 indexed citations
13.
Duley, John A., Ming Ni, Catherine Shannon, et al.. (2015). Towards a test to predict 5-fluorouracil toxicity: Pharmacokinetic data for thymine and two sequential metabolites following oral thymine administration to healthy adult males. European Journal of Pharmaceutical Sciences. 81. 36–41. 19 indexed citations
14.
Goldstein, David, Melanie L. Bell, Phyllis Butow, et al.. (2014). Immigrants' perceptions of the quality of their cancer care: an Australian comparative study, identifying potentially modifiable factors. Annals of Oncology. 25(8). 1643–1649. 36 indexed citations
15.
Alamgeer, Muhammad, Vinod Ganju, Beena Kumar, et al.. (2014). Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Research. 16(2). R44–R44. 43 indexed citations
16.
Hoff, Daniel D. Von, Thomas J. Ervin, Francis P. Arena, et al.. (2013). Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).. Journal of Clinical Oncology. 31(4_suppl). LBA148–LBA148. 90 indexed citations
17.
Harris, Marion. (2008). WHY ALL YOUNG BOWEL CANCER PATIENTS SHOULD BE SCREENED FOR LYNCH SYNDROME. ANZ Journal of Surgery. 78(7). 531–532.
18.
Harris, Marion, Ingrid Winship, & Merle Spriggs. (2005). Controversies and ethical issues in cancer-genetics clinics. The Lancet Oncology. 6(5). 301–310. 49 indexed citations
19.
Harris, Marion. (2004). Monoclonal antibodies as therapeutic agents for cancer. The Lancet Oncology. 5(5). 292–302. 232 indexed citations
20.
Harris, Marion, Mark Rosenthal, David L. Ashley, & Lawrence Cher. (2001). An Australian experience with temozolomide for the treatment of recurrent high grade gliomas. Journal of Clinical Neuroscience. 8(4). 325–327. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mariana Brandão Breakdown of academic impact, for papers by Shelly Seward Breakdown of academic impact, for papers by Jana Barinoff Breakdown of academic impact, for papers by Shuncong Wang Breakdown of academic impact, for papers by Ciara C. O’Sullivan Breakdown of academic impact, for papers by Claudia Andreetta Breakdown of academic impact, for papers by Hamdy A. Azim Breakdown of academic impact, for papers by Sara López‐Tarruella Breakdown of academic impact, for papers by Claudia Omarini Breakdown of academic impact, for papers by Aránzazu Manzano
Rankless by CCL
2026